What's new

EMEA-002875-PIP02-24

EMEA-002875-PIP02-24

Jun 23, 2025 - 13:50
 0
EMEA-002875-PIP02-24
EMEA-002875-PIP02-24
Read More

Tags:

Previous Article

STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity...

Next Article

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben ...

Related Posts

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 2, 2025  0

Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive

Orphan designation: small-interfering RNA against solub...

Jun 5, 2025  0

CTIS newsflash - 10 June 2025

Jun 12, 2025  0